Description

BeOne Medicines: Initiation of Coverage- 20 expected R&D milestones In The Next 18 Months Signalling A Massive Upside?

BeOne Medicines recently announced its financial results for the second quarter of fiscal year 2025. The company reported significant financial and strategic progress, reinforcing its position in the market. Breaking down the results, BeOne’s revenue reached $1.3 billion, reflecting a robust 42% year-over-year growth. This growth was notably driven by the performance of BRUKINSA, BeOne’s leading BTK inhibitor. BRUKINSA generated $950 million in global revenue, marking a 49% increase compared to the previous year, due to strong demand across various geographies.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!